Kidney outcomes with SGLT2 inhibitors in patients with diabetes and an insulin‐deficient phenotype: A real world analysis
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.16329 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Anat Tsur und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Clalit Health Services, Jerusalem, Israel. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetic Nephropathies, Diabetes Mellitus, Type 2, Insulin. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aim Diabetic kidney disease (DKD) is a major complication of diabetes, including in insulin‐deficient phenotypes, yet data on kidney outcomes with sodium‐glucose cotransporter 2 inhibitors (SGLT2i) in this population are limited. This study investigates the impact of SGLT2i on kidney outcomes in patients with insulin‐deficient diabetes using real world data. Materials and Methods This retrospective cohort study utilized data from a large Health Maintenance Organization in Israel and included 12,530 propensity score‐matched adults with insulin‐deficient diabetes. Patients were categorized into SGLT2i users and non‐users and followed for a median of 1657 days. The primary outcome was a composite of ≥50% decline in eGFR to
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, Clalit Health Services, Jerusalem, Israel.
- The Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
- Department of Endocrinology and Metabolism, Hadassah Medical Center, Jerusalem, Israel.
ORCID-Profile: Anat Tsur, Avivit Cahn
Zitieren
APA
Tsur, A., Cahn, A., Hanoch, L., & Pollack, R. (2025). Kidney outcomes with SGLT2 inhibitors in patients with diabetes and an insulin‐deficient phenotype: A real world analysis. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16329
Vancouver
Tsur A, Cahn A, Hanoch L, Pollack R. Kidney outcomes with SGLT2 inhibitors in patients with diabetes and an insulin‐deficient phenotype: A real world analysis. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16329
BibTeX
@article{Tsur2025,
author = {Tsur, Anat and Cahn, Avivit and Hanoch, Lior and Pollack, Rena},
title = {Kidney outcomes with SGLT2 inhibitors in patients with diabetes and an insulin‐deficient phenotype: A real world analysis},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.16329}
}
EUVIMED